Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function

Table 2 Cohort studies (2 reports) and randomized controlled trial (3 reports)

Ref.	Group	Patient number	Therapy for HCC	Male/Female	Age (yr)	Child-Pugh A/B/C	Maximum tumor size (mm)	Study design
Okabayashi et al[56]	LES-BCAA	40	surgery	29/11	65.7 ± 8.6	33/7/0	ND	cohort
2008	control	72		55/17	68.3 ± 8.1	62/10/0	ND
Kuroda et al[57]	LES-BCAA	20	RFA	13/7	65.6 ± 7.0	8/11/1	20.2 (median)	cohort
2010	control	15		9/6	66.0 ± 8.1	6/8/1	19.8 (median)
Morihara et al[58]	LES-BCAA	10	RFA	8/2	73.5 ± 8.5	9/1/0	20.0 ± 10.7	RCT
2012	Morning-BCAA	10		8/2	66.9 ± 9.7	7/3/0	24.3 ± 7.7
	control	10		7/3	69.3 ± 8.0	7/3/0	24.4 ± 7.7
Takeshita et al[59]	LES-BCAA	28	TACE	19/9	69.1 ± 8.231	6.107 ± 1.315 (score)	ND	RCT
2009	control	28		21/7	70.6 ± 9.745	5.53 ± 0.516 (score)	ND
Harima et al[60]	LES-BCAA	13	HAIC	11/2	64.5 ± 9.5	6/7/0	77.7 ± 50.5	RCT
2010	control	10		8/2	66.4 ± 12.8	6/4/0	88.0 ± 39.7

LES-BCAA: Late evening snack using branched-chain amino acid; Morning-BCAA: Morning BCAA administration; RFA: Radiofrequency ablation; TACE: Trans-catheter arterial chemoembolization; HAIC: Hepatic arterial infusion chemotherapy; ND: Not done; RCT: Randomized control trial.